11/4/2026

speaker
Jordan
Conference Operator

Thank you for standing by. My name is Jordan and I'll be your conference operator today. At this time, I'd like to welcome everyone to the AccuRay first quarter fiscal 2027 financial results call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there'll be a question and answer session. If you'd like to ask a question, simply press star followed by the number one on your telephone keypad. Thank you. I would now like to turn the conference over to Steve Munro, Vice President of Financial Planning and Analysis. You may begin.

speaker
Steve Munro
Vice President of Financial Planning and Analysis

Thank you and good afternoon, everyone. Welcome to AccuRay's conference call to review financial results for the first quarter of fiscal year 2027, which ended September 30th, 2026. During our call this afternoon, management will review financial results for the quarter as well as recent corporate developments. Joining us on today's call are Steve LaNeve, Accurate's President and Chief Executive Officer, and Ali Pervaiz, Accurate's Chief Financial Officer. Before we begin, I would like to remind everyone that our discussion today includes forward-looking statements. Actual results may differ materially from those contemplated or implied by these forward-looking statements. Factors that could cause actual results to differ materially are outlined in today's earnings release and in our filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements except as required by law. In addition, we will discuss certain non-GAAP financial measures. Reconciliations for the most directly comparable GAAP measures are provided in today's earnings release. There is also a supplemental slide presentation available on the investor relations section of our website. With that, let me turn the call over to Steve LaNeve.

speaker
Steve LaNeve
President and Chief Executive Officer

Thank you, Steve. Good afternoon, everyone, and thank you for joining us. The end of our first quarter of fiscal 2027 marks approximately one year since I joined AccuRay. Over the past year, we have made significant progress against the transformation plan we laid out. We made changes across the company to strengthen our financial foundation, lowered our cost structure, improved our organization, sharpened our commercial focus, and positioned Accuray for sustainable growth. But rather than spending time looking back, today I want to focus on where we are going. As I said on our last call, fiscal 2026 was a year of transformation. Fiscal 2027 is about execution. During the first quarter, we made significant progress across several areas. We continue to expand our global install base, which enlarges the foundation for recurring service and solutions revenue and enables margin expansion. Service revenues increased, service margins improved, operating expenses remained well controlled, We strengthened our financial position and we continued to advance our product innovation roadmap through strategic partnerships. At the same time, our product orders and revenue performance did not meet our expectations, with geopolitical and other market factors in China representing a key headwind to product sales performance. Importantly, We continue to see strong underlying commercial opportunities across the business. We have a sizable pipeline, a high degree of customer and distributor engagement, and a growing portfolio of innovations that we believe further differentiates our solutions in the marketplace. Our priority now is execution. Converting that pipeline and customer interest into orders, translating orders into product revenue, and leveraging our installed base to drive an increasingly durable stream of recurring service revenue and company-wide profitability. Strategic partnerships and innovation. Over the past year, we have been deliberate about where AccuRay can differentiate and where partnerships can help us move faster rather than relying primarily on internal product development, which AccuRay had done historically. During the first quarter, we took two important steps forward in this regard. We entered into a definitive agreement with Raysearch to accelerate our online adaptive radiation therapy strategy, combining AccuRay's treatment delivery and imaging capabilities with research as treatment planning and workflow software, initially on RADxACT with a planned extension to CyberKnife. Online adaptive radiation therapy allows treatment plans to be adjusted immediately before treatment based on the patient's anatomy at the time of delivery. The solution is designed to support more personalized treatments while helping clinics work more efficiently. We also advanced our collaboration with Samsung Neurologica to pursue volumetric imaging capabilities for CyberKnife, bringing together their imaging expertise with our strengths in robotic radiosurgery, precision treatment delivery, and real-time motion management. Leading practitioners have emphasized that volumetric imaging can enhance visualization of patient anatomy in the treatment environment and support future clinical workflows. Professor Nicholas Van Os of the Royal Marston spoke on our behalf during ASTRO where he noted that seeing the target and surrounding anatomy together, the time of treatment could help us make more informed decisions for each patient. Looking further ahead, this could open up new possibilities for adapting treatment to the patient's anatomy of the day. alongside real-time motion management during delivery. That perspective reflects the opportunity we see in bringing advanced imaging, adaptation, and motion management together in the broader direction we heard from clinicians at ASTRO. Professor Van Os presented long-term results from randomized Phase III, PACE-A trial comparing surgery with stereotactic body radiation therapy or SBRT for localized prostate cancer. The trial randomized 123 patients and at a median follow-up of eight years, the estimated five-year freedom from biochemical or clinical failure rate was 94.8% with SBRT and 94.1% with prostatectomy. These findings are notable because they provide evidence supporting SBRT as an effective non-surgical treatment option with disease control comparable to prostatectomy. Importantly, the study also evaluated patient reported quality of life outcomes. At five years, the median sexual function score had declined 42 points for patients treated with surgery compared with 17 points for patients treated with SBRT. Based on these results, the investigators concluded that SBRT had significant advantages over surgery in preserving sexual function and sexual quality of life at five years. For Accuray, these clinical developments reinforce where we believe radiation oncology is heading, toward greater precision through emotion management, personalization, and adaptation. with an increasing focus on protecting healthy tissue and preserving quality of life. By combining our strengths in precision treatment, delivery, and real-time motion management with enhanced imaging and adaptive capabilities, we believe we can further differentiate our platforms and deliver greater value for clinicians and patients. Commercial and operational execution. Our focus now is translating innovation and clinical differentiation of this type into stronger commercial performance. Over the past year, we have made significant changes to strengthen our commercial organization and improve execution. We changed our commercial leadership, Realigned our sales and marketing organizations, expanded our sales enablement capabilities, and created a dedicated channel management organization designed to improve both our relationships with distributors and their performance. Our new commercial leadership team has also made important changes in the U.S. organization and enhanced our go-to-market approach with channel partners. We expect these actions to increase commercial accountability, improve pipeline conversions, and drive more consistent execution, particularly across Eastern Europe and APAC. At the same time, the continued growth of our installed base is increasing the scale and strategic importance of our services and solutions business. Our installed base has now surpassed 1,100 systems globally. supporting more than $230 million of recurring annual revenue and creating an increasingly meaningful and durable foundation for the company. The opportunity extends beyond revenue growth. As the install base expands, we also have an opportunity to improve the profitability of that recurring revenue stream. Service gross margin improved by 410 basis points in Q1. compared with FY26 trailing 12-month service gross margin of 31%. We continue to focus on pricing discipline, contract renewals, remote diagnostics, parts consumption, and a greater mix of higher margin solutions to drive further improvement. We have also increased the rigor of our services and solutions operating model with a focus on sustaining margin expansion over the next several years. Taken together, growth in the installed base, increasing recurring service revenue, and continued margin expansion provide an important source of stability and earnings leverage as we work to return product orders and revenue to stronger levels. In addition, Our efforts over the last year to lower our cost structure continued to bear fruit. Our operating costs, excluding restructuring costs, were approximately $13 million lower than in the first quarter of last year. We told you last year that we expected our transformation efforts to result in at least $25 million of annualized profitability improvement. And we have significantly exceeded that amount on an annualized basis from operating cost reductions alone. These are areas within our control. The opportunity now is to pair this operating discipline with stronger product and order performance. The financial foundation. Supporting these priorities is a stronger financial foundation. During the quarter, we received the $15 million cash investment associated with our previously announced PCW Financing Transaction. Following quarter end, stockholders approved the proposals necessary to advance the broader transaction, including the previously announced exchange of $40 million of term loan debt for convertible preferred equity. These actions are intended to reduce leverage, enhance liquidity, and provide greater flexibility to execute our strategy. We also welcomed Richard Randy Meyer to our board of directors. Randy brings more than 30 years of extensive healthcare, financial, and operational leadership experience. We look forward to benefiting from his perspective. Looking ahead, ultimately our strategy comes back to our purpose, expanding the curative power of radiation therapy to improve as many lives as possible while building a stronger, more competitive, and more profitable Accuray. With that, I'll turn the call over to Ali to discuss our first quarter financial performance in more detail.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API